107 results about "Immune inflammation" patented technology

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and / or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.

The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F1F0 ATP hydrolase associated disorders, and the like.

The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides novel 1,4-benzodiazepine-2,5-dione compounds, and methods of using novel 1,4-benzodiazepine-2,5-dione compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.

The present invention provides for the treatment, prevention, and / or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

The invention belongs to the technical field of medicines, discloses applications of andrographolide derivatives in preparation of medicines preventing and treating hepatic fibrosis, and relates to 15-benzylidene-14-deoxy-11,12-dehydroandrographolide derivatives and 3,19 esterified compounds thereof. Experiments prove that the compounds significantly inhibit human hepatic stellate cell LX-2 metastasis and activation, significantly reduce the fibrosis level of hepatic tissues of rats affected with hepatic fibrosis, reduce contents of extracellular matrix protein (ECM) related components, significantly reduce the level of immune inflammation correlation factors of rats affected with hepatic fibrosis, effectively inhibit immuno-inflammatory responses, inhibit hepatic stellate cell activation in hepatic tissues, and promote collagen degradation. The compounds are used as active components for preparing the anti-hepatic fibrosis medicines, and are efficient and low in toxicity, thus providing a novel medicine route for hepatic fibrosis treatment and prevention, and expanding the optional range of clinical medicine application. The compounds and the applications have good development prospects.

A genetic locus and corresponding family of proteins associated with regulation of immune development, function, and cell survival are provided. The locus comprising the TIM family is genetically associated with immune dysfunction, including atopy, autoimmunity, inflammatory bowel disease, dysplasia, and susceptibility to blood-bourne infectious diseases. Polymorphisms in the human TIM-1 gene and exposure to Hepatitis A Virus (HAV) are shown to be associated with protection from the development of atopy.

The invention provides an antagonistic peptide which can simulate the key sequence for bonding MD2 and LPS and competitively antagonize the specific bonding which is generated by LPS and MD2, thus achieving the mitigation of the excessive activation of the immune inflammatory cells of LPS and further easing the caused excessive septic damages to the body. The amino acid sequence of the antagonist peptide includes: a sequence 1 of Lys Thr Val Pro Asp Asn His; and the sequence 2 of Ile Gly Lys Phe Leu Tyr Arg. The peptide can effectively mitigate the septic inflammation damage which is induced by the intracellular toxin LPS, thus significantly improving the survival rate of mouses which are infected by the intracellular toxin and maintaining the body immune defense function at the same time of specifically inhibiting the excessive stimulation of the LPS on the inflammatory cells. The antagonistic peptide can be used for preparing the treatment drugs of the inflammatory diseases which are caused by gram-negative bacteria and are related to a toll-like receptor protein.

The invention relates to the field of biological medicine, in particular to a preparation method for obtaining immune cell exosome carrying a CAR through separation. Specifically CAR immune cell is activated through specific antigen, produced exosome is further analyzed, separated, purified and enriched, and finally the immune cell exosome carrying the CAR is obtained. The exosome can be applied to the treatment of various diseases, such as cancer and severe infectious diseases, overcomes adverse reactions, such as immune inflammation storm, during CAR cell therapy, enhances the CAR tissue infiltration capacity, further has the advantages of high convenience in storage and transportation, and provides a novel strategy for the treatment of relevant diseases.

The invention relates to a specific blocking agent of a Toll-like receptor 9 (TLR9). The blocking agent is a nonmethylated CpG nucleotide sequence segment, the core structure of which is a CGCG nucleotide sequence, and the length of the nonmethylated CpG nucleotide sequence segment is 12-30 nucleotides. The blocking agent can be specifically combined with the TLR9, can block the combination between other irritant aglucons and the TLR9 and inhibit the proinflammatory effect mediated by the receptor, and can be used for the adjuvant treatment of inflammatory resistance and allergy resistance and the preparation of an experiment reagent of immune inflammation.

The invention relates to glucagon-like peptide-1 (GLP-1) acceptor agonists (comprising: macromolecular agonists, such as GLP-1 and derivatives thereof, and exendins and derivatives thereof; and micromolecular agonists, such as geniposides) used for treating diseases, such as pains, especially chronic pains, comprising neuropathic pains, cancer pains, diabetic pains, immune inflammation pains, pains in back and loin, and the like which can be treated through activating a central nervous system comprising a spinal cord GLP-1 acceptor.

The invention relates to new application of paeonol and derivatives thereof in the pharmacy field. The animal experiment research shows that paeonol and derivatives thereof can obviously relieve or eliminate the inflammatory reaction of the local tissue of the eye with immunologic conjunctivitis, obviously reduce the infiltration of acidophilic cells and the degranulation of mast cells in the conjunctiva tissue, obviously relieve the inflammatory reaction of the anterior segment of the eye with uveitis, reduce the infiltration of inflammatory cells in the vitreous body and retinal tissue, effectively control the non-infectious immune inflammation of the dry eye, and obviously relieve the inflammatory reaction of the animal model eye with chronic conjunctivitis; and the clinical experiment research shows that the paeonol can be used for effectively treating eye diseases such as sclerotitis and the like. The invention provides a medicament for treating eye diseases, which has the advantages of exact curative effect and wide source and is safe and convenient; and the medicament can be combined with one or more pharmaceutically acceptable carriers or excipients to be prepared into a pharmaceutical composition or preparation of the paeonol and derivatives thereof.

The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).

The invention relates to an extract of traditional Chinese medicine unifoliate clematis and an application of the extract as a medicine for treating rheumatoid arthritis. The extract is a unifoliate clematis extract which takes the traditional Chinese medicine unifoliate clematis as a raw material, is produced under certain technological conditions and contains various triterpenoid saponin components. The pharmacological experiments of animal general inflammation and immune inflammation models prove that the extract provided by the invention has an obvious treatment effect and has an important value for treating rheumatoid arthritis.

The invention relates to a heterocyclic group contained amino-methanol derivative, its salt, its synthetic method and its use, and belongs to the medical field. The heterocyclic group contained aminomethanol derivative and its salt are used for preparing medicines for immune suppression and organ transplant repulsion reaction treatment, or medicines for treating immune inflammation diseases, such as Multiple Sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

The invention relates to a preparation method for acquiring effective substance groups with anti-ulcerative-colitis activity by separation from callicarpa kwangtungensis and compound extract thereof and application of the effective substance groups to preparation of medicines for treating immune inflammations. Particularly, the effective substance groups are acquired by adoption of a membrane separation focused separation technology and used for preparation of medicines for treating immune inflammations including ulcerative colitis.

The invention relates to application of a ginsenoside Rb1 and Rd combination to preparation of a medicine for treating photoreceptor cell death related diseases. A mouse model suffering from retinal light damage is adopted to simulate the common key pathological links in the process of various degenerative retinal diseases so as to research the intervention effects of the ginsenoside Rb1 and Rd combination on the mouse model suffering from retinal light damage, and the results show that the medicinal combination can maintain the format of the retina outer nuclear layer, effectively prevent the retina outer nuclear layer from degenerative damage and thickness reduction, inhibit death of photoreceptor cells, block oxidative stress of retinal pigment epitheliums and photoreceptor cells, effectively inhibit retinal damage related immuno-inflammatory responses and remarkably improve the degenerative retinal diseases. Therefore, the ginsenoside Rb1 and Rd combination can be used for preparing the medicine for treating various degenerative retinal diseases including age-related macular degeneration, retinal pigment degeneration, Stargardt disease, cone-rod cell dystrophy, diabetic retinopathy and the like.

The present invention relates to compositions and methods for the treatment of immuno-inflammatory conditions comprising the administration of a polyphenolic phytoalexin compartmentalized in a biocompatible and / or biodegradable polymeric carrier, and to the use of biocompatible and / or biodegradable polymeric carriers comprising resveratrol and block copolymers and these compositions with an additional compartmentalized pharmaceutically active agent.

The invention discloses iodine-loaded bioactive glass for wound care and application of the iodine-loaded bioactive glass. The properties that chitosan is not dissolved in an alkaline medium and formscondensation / precipitation when meeting an alkaline medium are utilized to obtain a chitosan microsphere template, and hollow bioactive glass is prepared from a compound containing various inorganicelements (silicon, calcium, sodium, phosphorus and the like) through a sol-gel-template method. The iodine-loaded bioactive glass is prepared by adopting a sealing temperature control sublimation andadsorption technology, and the composition has both bioactive glass particles and iodine molecules, can effectively promote healing of hard and soft tissue injuries of the human body, can also play along-lasting role of inhibiting / killing bacteria, has strong effects, low toxic and side effects and little immune inflammation response, and is convenient to store, carry and use.

The invention provides application of ABT-263 in preparation of a medicine for inhibiting corneal transplantation immunological rejection, and belongs to the technical field of chemical medicines. The invention provides an application of a micromolecular Bcl-2 inhibitor Navitclax(ABT-263) capable of inducing apoptosis in preparation of a product for inhibiting immunological rejection after corneal transplantation. Researches show that the Bcl-2 inhibitor ABT-263 can prolong the survival time of a corneal graft after corneal transplantation, reduce immune inflammatory response in the corneal graft, maintain transparency of the corneal graft and reduce immunological rejection, and can be used for preventing and treating diseases such as immunological rejection after corneal transplantation, corneal endothelial cell decompensation and the like.

The invention relates to an application of tanshinone I shown in a formula I to the treatment of a microglia-mediated disease, in particular to an application of tanshinone I to the preparation of a medicament for treating and / or preventing the microglia-mediated disease, in particular to an application of tanshinone I to preparation of a medicament for treating and / or preventing psychoneuroimmunology chronic inflammatory diseases caused by microglia-mediated neurotoxic effects. The tanshinone I provided by the invention has the novel functions of remarkably suppressing microglia cell-activated and induced cell death, suppressing the generation and expression of inflammatory mediators, i.e., NO and TNF alpha of microglia cells, and remarkably lowering the cell toxicity of activated microglia cells on neurons, the tanshinone I can be applied to prevention and treatment of brain immune inflammation-related diseases such as Alzheimer's disease, Parkinson's disease, and the like. The formula I is shown in the specifications.

The invention discloses an extraction method of falcate dolichos root or leaf glucoside A. The method comprises the following steps: (1) taking falcate dolichos root or leaf herbs, adding alcohol aqueous solution for reflux extraction, wherein the weight of the alcohol aqueous solution is 6-12 times of that of falcate dolichos root or leaf herbs; (2) recovering the falcate dolichos root or leaf extract solution obtained from the step 1 under reduced pressure to alcohol till no alcohol taste exists, and adding water or alcohol to liquid medicine; (3) adding hydrochloric acid into the liquid medicine obtained from the step 2 till the pH value is 1-6, and adding sodium chloride into the liquid medicine till the salt concentration to 0.1-2mol / L; (4) placing the liquid medicine obtained from the step (3) on a macroporous adsorption resin column for separation; (5) cleaning and purifying with alcohol aqueous solution, of which the volume is 4-10 times of the column volume of the macroporous adsorption resin column, eluting with alcohol aqueous solution, of which the volume is 4-10 times of the column volume of the macroporous adsorption resin column, collecting the eluant, and drying to obtain falcate dolichos root or leaf glucoside A. The invention further discloses an extraction method of total saponins of falcate dolichos root or leaf, and the application of the falcate dolichos root or leaf glucoside A, the total saponins of falcate dolichos root or leaf, falcate dolichos root or leaf glucoside A hydrolysate and salt thereof and falcate dolichos root or leaf glucoside A derivate in preparing immune-inflammation resistant drugs.

The invention relates to the field of medical appliances, and particularly relates to a method for treating an animal-derived collagen fiber material. The method is performed by treating the animal-derived collagen fiber material with a salt solution containing polyethylene glycol and oxidants. After a biological valve treated by the method provided by the invention is implanted to an acceptor, immune inflammation reaction is not generated.

The invention provides a use of Nitrosporeusines A in preparation of drugs for treating immune-inflammation and especially for treating rhinitis. A contrast test utilizing terfenadine and diclofenac sodium as control groups proves that Nitrosporeusines A has clear effects. Nitrosporeusines A is first disclosed in the invention. Nitrosporeusines A has a novel skeleton type, strong activity of treating rhinitis and substantive distinguishing features, and obviously develops rhinitis prevention and treatment.

The invention discloses application of 2-(2-difluoromethyl benzimidazole-1-yl)-4,6-dimorpholinyl-1,3,5-triazine (ZSTK474 for short) to preparation of a medicine for treating autoimmune and inflammatory diseases. Experimental results prove that the ZSTK474 can inhibit the differentiation of human immune dendritic cells, the maturity of the lipopolysaccharide (LPS) activated human immune dendritic cells, the antigen uptake capacity of immature dendritic cells, the antigen presenting capacity of mature dendritic cells and T cell proliferation reaction stimulated by the dendritic cells, and particularly can reduce the morbidity degree of mouse experimental autoimmune encephalomyelitis, so the ZSTK474 is expected to become a medicine for treating autoimmune and inflammatory diseases such as multiple sclerosis, acute disseminated encephalomyelitis and the like clinically.

The invention belongs to the technical field of drugs, and concretely relates to an application of proadifen and pharmaceutically acceptable salts thereof in the preparation of inflammation associated disease prevention and treatment drugs. Above inflammations comprise aseptic inflammations and immune inflammations. The use of proadifen in the preparation of anti-inflammation drugs is disclosed in the invention for the first time, and a result of copper sulfate induced zebra fish inflammation model experiment researches shows that proadifen can promote regression of neutral granulocytes in the inflammation positions, and has inflammation prevention and elimination effects. The proadifen has obvious an anti-inflammatory effect on inflammation associated diseases, and can be used to prepare the inflammation associated disease prevention and treatment drugs.

Disclosed are compositions and methods for the reduction of C5a mediated immune inflammation. The methods, in various aspects, may include the step of administering a C5aR antagonist to a subject in need of such treatment. In one aspect, the subject in need may have a lysosomal acid storage disease. Therapeutic kits and articles of manufacture are also disclosed.